This kit uses RT-PCR to detect breakpoint cluster region-abelson leukemia (BCR-ABL) fusion gene in plasma or formalin-fixed paraffin-embedded tissue (FFPE). Test results may serve as a reference for clincial evaluation fo defined BCR-ABL fusion gene in chronic myeloid leukemia patients. Confirmed mutation: recommended therapies include imatinib, treatment options and drug efficacy evaluation.
Based on high-efficiency enzymatic processing technology, the test uses specific gene sequences as PCR targets. Human genomic sequence is used as internal quality control.
